242 related articles for article (PubMed ID: 1505152)
1. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
[TBL] [Abstract][Full Text] [Related]
2. Specific and dose-dependent enzyme induction by omeprazole in human beings.
Rost KL; Brösicke H; Heinemeyer G; Roots I
Hepatology; 1994 Nov; 20(5):1204-12. PubMed ID: 7927253
[TBL] [Abstract][Full Text] [Related]
3. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
Rost KL; Roots I
Clin Pharmacol Ther; 1994 Apr; 55(4):402-11. PubMed ID: 8162667
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
[TBL] [Abstract][Full Text] [Related]
5. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
6. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost KL; Brockmöller J; Esdorn F; Roots I
J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
Böttiger Y; Tybring G; Götharson E; Bertilsson L
Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
[TBL] [Abstract][Full Text] [Related]
8. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
9. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
10. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
Tybring G; Böttiger Y; Widén J; Bertilsson L
Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
[TBL] [Abstract][Full Text] [Related]
12. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
14. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
15. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
Chang M; Tybring G; Dahl ML; Götharson E; Sagar M; Seensalu R; Bertilsson L
Br J Clin Pharmacol; 1995 May; 39(5):511-8. PubMed ID: 7669487
[TBL] [Abstract][Full Text] [Related]
16. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
[TBL] [Abstract][Full Text] [Related]
17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
19. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
20. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
